# US 11,111,541 B2 · Diagnostic MiRNA markers for Parkinson's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,111,541 B2
- Document ID: US11111541B2
- Status: Granted
- Kind: B2
- Application number: 16/004,775
- Filed: 2018-06-11
- Published: 2018-11-29
- Granted: 2021-09-07
- Earliest claimed: 2012-11-16
- Assignees: Universitat Des Saarlandes
- Applicants: Universitat des Saarlandes
- Inventors: Andreas Keller; Cord Friedrich Stahler; Jan Kirsten; Eckart Meese; Christina Backes; Petra Leidinger
- Web page: https://patentgrep.com/patent/US11111541B2

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The invention relates to methods for diagnosing Parkinson's Disease PAD) with miRNA markers. Towards the identification of biomarkers for diagnosis of PD, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified.

## Claims

### Claim 1

A method of analyzing miRNA in a blood sample taken from a patient, said method comprising the step of:
a) determining in said blood sample expression level of: miRNA having the nucleotide sequence of SEQ ID NO: 142 and miRNA having the nucleotide sequence of SEQ ID NO: 59.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising determining expression level miRNA having the nucleotide sequence of SEQ ID NO: 69.

### Claim 3 (depends on 2)

The method according to claim 2, comprising determining expression level of: miRNA having the nucleotide sequence of SEQ ID NO: 69, miRNA having the nucleotide sequence of SEQ ID NO: 142, miRNA having the nucleotide sequence of SEQ ID NO: 2, miRNA having the nucleotide sequence of SEQ ID NO: 59, miRNA having the nucleotide sequence of SEQ ID NO: 58, and miRNA having the nucleotide sequence of SEQ ID NO: 65.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the determination of the expression level in step (a) is obtained by use of a method selected from the group consisting of a Sequencing-based method, an array based method and a polymerase chain reaction (PCR) based method.

### Claim 5 (depends on 1)

The method according to claim 1, comprising determining expression levels of at least 2, 3, 4, 5, or 6 miRNAs.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the patient is a healthy subject.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the patient is suffering from or at risk of developing Parkinson's Disease (PD) or a neurological disease other than PD.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the other neurological disease is selected from the group consisting of Alzheimer's disease (AD), Cognitive Impairment (MCI), Multiple Sclerosis (MS), Mild Depression, Bipolar Disorder (BD), and Schizophrenia.

### Claim 9 (depends on 1)

The method of claim 1, wherein the blood sample is a blood cell sample.

### Claim 10 (depends on 7)

The method of claim 7, wherein the patient has early symptoms of Parkinson's Disease (PD) or a neurological disease other than PD.

### Claim 11 (depends on 4)

The method according to claim 4, wherein the determination of the expression level in step (a) is obtained by next-generation sequencing (NGS) or quantitative reverse transcription PCR (qRT-PCR).

### Claim 12 (depends on 1)

The method according to claim 1, further comprising determining expression level of miRNA having the nucleotide sequence of SEQ ID NO: 2.

### Claim 13 (depends on 1)

The method according to claim 1, further comprising determining expression level of miRNA having the nucleotide sequence of SEQ ID NO: 58.

### Claim 14 (depends on 1)

The method according to claim 1, further comprising determining expression level of miRNA having the nucleotide sequence of SEQ ID NO: 65.